Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Portfolio Pulse from Lara Goldstein
Imperial College London's Centre for Psychedelic Research will begin a government-funded study in October to assess psilocybin-assisted therapy for gambling addiction. The University of Calgary will also launch a clinical trial in October to study the effects of psilocybin paired with Motivational Enhancement Therapy on heavy drinking in patients with Alcohol Use Disorder. In January 2024, a Phase 2 clinical trial will begin to assess the feasibility, safety, and preliminary efficacy of one psilocybin dose to alleviate opioid-refractory pain in advanced cancer patients. This trial will use Filament Health's (OTC:FLHLF) natural psilocybin and is funded by Cy Biopharma and Pancreatic Cancer North America.

August 24, 2023 | 12:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Filament Health's natural psilocybin will be used in a Phase 2 clinical trial starting in 2024 to assess its efficacy in alleviating opioid-refractory pain in advanced cancer patients.
The use of Filament Health's natural psilocybin in a Phase 2 clinical trial could potentially increase the company's visibility and credibility in the medical community. If the trial results are positive, it could lead to increased demand for the company's product, potentially boosting its stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 70